[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fneaCgppWhnceZvCQJwhGkQMzr-RUESgj0E-e0UJSfPc":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":34,"phaseBuckets":85,"rows":92},"Institut National de la Santé Et de la Recherche Médicale, France",[4],371,false,104,15,789928,19,293,[14,17,19,22,24,27,30,32],{"name":15,"count":16},"Healthy",11,{"name":18,"count":16},"Parkinson's Disease",{"name":20,"count":21},"Stroke",9,{"name":23,"count":21},"Parkinson Disease",{"name":25,"count":26},"Huntington Disease",7,{"name":28,"count":29},"Multiple Sclerosis",5,{"name":31,"count":29},"Tuberculosis",{"name":33,"count":29},"Influenza",[35,40,45,50,55,60,65,70,75,80],{"nctId":36,"briefTitle":37,"date":38,"intervention":39},"NCT04183023","Population Genomic Diversity of France","2022-02-19","Collection of a salivary sample",{"nctId":41,"briefTitle":42,"date":43,"intervention":44},"NCT03209102","Emotional Regulation and Impulsivity Among Adolescents with Borderline Personality Disorder","2024-10-04","salivary collections of amylase and cortisol",{"nctId":46,"briefTitle":47,"date":48,"intervention":49},"NCT05290051","Prospective Study to Assess Medical Performance of Optical Mapping and Long Read Sequencing in Detecting Numerical and Structural Chromosome Abnormalities","2025-03-26","Optical Genome Mapping",{"nctId":51,"briefTitle":52,"date":53,"intervention":54},"NCT04902807","Conception of a Diagnosis, Prognosis and Therapeutic Decision Tool for Patients With Autoimmunity and Inflammation","2025-05-14","Collection of samples",{"nctId":56,"briefTitle":57,"date":58,"intervention":59},"NCT06278337","X-linked Moesin Associated Immunodeficiency","2026-08-12","genetic restrospective study",{"nctId":61,"briefTitle":62,"date":63,"intervention":64},"NCT06446960","The Role of Peripheral Afferents in Modulating Post-stroke Central Pain","2026-09-08","Lidocaine 20mg\u002Fml",{"nctId":66,"briefTitle":67,"date":68,"intervention":69},"NCT04736381","Impact of the Microbiota on the Likelihood of Renal Graft Rejection","2027-01-07","Belatacept Injection [Nulojix]",{"nctId":71,"briefTitle":72,"date":73,"intervention":74},"NCT06660108","MOLECULAR BASIS OF LANGUAGE DEVELOPMENT AND ASSOCIATED DISORDERS","2027-03-25","blood draw",{"nctId":76,"briefTitle":77,"date":78,"intervention":79},"NCT06024421","Evaluation of Tolerance and Pharmacokinetic Profile of High Doses of Favipiravir in Healthy Volunteers","2027-06","favipiravir",{"nctId":81,"briefTitle":82,"date":83,"intervention":84},"NCT04186650","Ex Vivo Gene Therapy Clinical Trial for RDEB Using Genetically Corrected Autologous Skin Equivalent Grafts","2027-06-09","COL7A1-SIN retroviral vector engineered autologous tissue-engineered skin",[86,87,88,89,90,91],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[93,118,136,154,178,199,225,272,310,335,360,382,410,436,454,479,500,540,558,580,606,632,667,685,703,721,739,757,775,793,811,829,856,882,900,926,944,970,996,1014,1044,1062,1080,1098,1116,1141,1167,1192,1219,1237,1261,1296,1320,1345,1369,1394,1420,1443,1466,1491,1514,1540,1558,1587,1610,1635,1659,1683,1709,1733,1757,1775,1801,1819,1837,1861,1885,1917,1950,1974,1999,2025,2053,2071,2089,2111,2136,2154,2172,2199,2225,2249,2275,2302,2320,2338,2363,2386,2411,2435,2460,2484,2508],{"intervention":64,"totalTrials":94,"cells":95},1,{"EARLY_PHASE1":96,"PHASE1":99,"PHASE2":101,"PHASE3":103,"PHASE4":114,"NA":116},{"trials":97,"activeCount":98},[],0,{"trials":100,"activeCount":98},[],{"trials":102,"activeCount":98},[],{"trials":104,"activeCount":94,"soonestReadout":63},[105],{"nctId":61,"briefTitle":62,"status":106,"phases":107,"primaryCompletion":63,"completion":63,"start":108,"enrollment":109,"conditions":110,"interventions":111},"RECRUITING",[89],"2024-02-09",36,[20],[64,112,113],"Levobupivacaine Hydrochloride 1.25 MG\u002FML","Sodium Chloride 0.9% Inj",{"trials":115,"activeCount":98},[],{"trials":117,"activeCount":98},[],{"intervention":112,"totalTrials":94,"cells":119},{"EARLY_PHASE1":120,"PHASE1":122,"PHASE2":124,"PHASE3":126,"PHASE4":132,"NA":134},{"trials":121,"activeCount":98},[],{"trials":123,"activeCount":98},[],{"trials":125,"activeCount":98},[],{"trials":127,"activeCount":94,"soonestReadout":63},[128],{"nctId":61,"briefTitle":62,"status":106,"phases":129,"primaryCompletion":63,"completion":63,"start":108,"enrollment":109,"conditions":130,"interventions":131},[89],[20],[64,112,113],{"trials":133,"activeCount":98},[],{"trials":135,"activeCount":98},[],{"intervention":113,"totalTrials":94,"cells":137},{"EARLY_PHASE1":138,"PHASE1":140,"PHASE2":142,"PHASE3":144,"PHASE4":150,"NA":152},{"trials":139,"activeCount":98},[],{"trials":141,"activeCount":98},[],{"trials":143,"activeCount":98},[],{"trials":145,"activeCount":94,"soonestReadout":63},[146],{"nctId":61,"briefTitle":62,"status":106,"phases":147,"primaryCompletion":63,"completion":63,"start":108,"enrollment":109,"conditions":148,"interventions":149},[89],[20],[64,112,113],{"trials":151,"activeCount":98},[],{"trials":153,"activeCount":98},[],{"intervention":44,"totalTrials":94,"cells":155},{"EARLY_PHASE1":156,"PHASE1":158,"PHASE2":160,"PHASE3":172,"PHASE4":174,"NA":176},{"trials":157,"activeCount":98},[],{"trials":159,"activeCount":98},[],{"trials":161,"activeCount":94,"soonestReadout":43},[162],{"nctId":41,"briefTitle":42,"status":163,"phases":164,"primaryCompletion":43,"completion":165,"start":166,"enrollment":167,"conditions":168,"interventions":171},"ACTIVE_NOT_RECRUITING",[88],"2026-01-03","2017-10-04",66,[169,170],"Borderline Personality Disorder","Adolescent Development",[44],{"trials":173,"activeCount":98},[],{"trials":175,"activeCount":98},[],{"trials":177,"activeCount":98},[],{"intervention":84,"totalTrials":94,"cells":179},{"EARLY_PHASE1":180,"PHASE1":182,"PHASE2":184,"PHASE3":193,"PHASE4":195,"NA":197},{"trials":181,"activeCount":98},[],{"trials":183,"activeCount":98},[],{"trials":185,"activeCount":94,"soonestReadout":83},[186],{"nctId":81,"briefTitle":82,"status":163,"phases":187,"primaryCompletion":83,"completion":83,"start":188,"enrollment":189,"conditions":190,"interventions":192},[87,88],"2020-01-10",3,[191],"Epidermolysis Bullosa Dystrophica, Recessive",[84],{"trials":194,"activeCount":98},[],{"trials":196,"activeCount":98},[],{"trials":198,"activeCount":98},[],{"intervention":200,"totalTrials":94,"cells":201},"LBT-999",{"EARLY_PHASE1":202,"PHASE1":204,"PHASE2":206,"PHASE3":219,"PHASE4":221,"NA":223},{"trials":203,"activeCount":98},[],{"trials":205,"activeCount":98},[],{"trials":207,"activeCount":94,"soonestReadout":212},[208],{"nctId":209,"briefTitle":210,"status":106,"phases":211,"primaryCompletion":212,"completion":213,"start":214,"enrollment":215,"conditions":216,"interventions":218},"NCT06930261","Dopaminergic Disruption Induced by Traumatic Coma: Dopaminergic Pathways Abnormalities and Biomarkers of Recovery Using MRI and 18F-LBT-999 PET",[88],"2027-09","2028-09","2025-01-14",55,[217],"Coma, Traumatic",[200],{"trials":220,"activeCount":98},[],{"trials":222,"activeCount":98},[],{"trials":224,"activeCount":98},[],{"intervention":226,"totalTrials":189,"cells":227},"Favipiravir",{"EARLY_PHASE1":228,"PHASE1":230,"PHASE2":241,"PHASE3":266,"PHASE4":268,"NA":270},{"trials":229,"activeCount":98},[],{"trials":231,"activeCount":94,"soonestReadout":78},[232],{"nctId":76,"briefTitle":77,"status":106,"phases":233,"primaryCompletion":78,"completion":234,"start":235,"enrollment":236,"conditions":237,"interventions":240},[87],"2027-11","2024-05-14",39,[238,239],"Infectious Disease","Pharmacology",[79],{"trials":242,"activeCount":98},[243,255],{"nctId":244,"briefTitle":245,"status":246,"phases":247,"primaryCompletion":248,"completion":249,"start":250,"enrollment":251,"conditions":252,"interventions":254},"NCT02329054","Efficacy of Favipiravir Against Ebola (JIKI)","COMPLETED",[88],"2015-05","2015-09","2014-12",126,[253],"Ebola Virus Disease",[226],{"nctId":256,"briefTitle":257,"status":258,"phases":259,"primaryCompletion":260,"completion":260,"start":261,"enrollment":262,"conditions":263,"interventions":265},"NCT02739477","Tolerance and Activity Evaluation of High Doses of Favipiravir Against Ebola Virus in the Semen","TERMINATED",[88],"2016-08","2016-04",2,[264],"Ebola Virus Survivor",[226],{"trials":267,"activeCount":98},[],{"trials":269,"activeCount":98},[],{"trials":271,"activeCount":98},[],{"intervention":273,"totalTrials":262,"cells":274},"Blood sampling",{"EARLY_PHASE1":275,"PHASE1":277,"PHASE2":279,"PHASE3":281,"PHASE4":283,"NA":285},{"trials":276,"activeCount":98},[],{"trials":278,"activeCount":98},[],{"trials":280,"activeCount":98},[],{"trials":282,"activeCount":98},[],{"trials":284,"activeCount":98},[],{"trials":286,"activeCount":94,"soonestReadout":291},[287,300],{"nctId":288,"briefTitle":289,"status":106,"phases":290,"primaryCompletion":291,"completion":291,"start":292,"enrollment":293,"conditions":294,"interventions":298},"NCT05806697","Investigation of AlzHeimer's Predictors in Subjective Memory Complainers - Extension Study",[91],"2030-10-09","2023-04-14",240,[295,296,297],"Alzheimer Disease","Memory Complaint","Memory Disorders",[273,299],"Lumbar puncture",{"nctId":301,"briefTitle":302,"status":246,"phases":303,"primaryCompletion":304,"completion":304,"start":305,"enrollment":306,"conditions":307,"interventions":309},"NCT01985139","Pleasure for Food and Endocannabinoids in Obesity",[91],"2019-11-21","2014-01",20,[308],"Obesity",[273],{"intervention":311,"totalTrials":94,"cells":312},"blood sample",{"EARLY_PHASE1":313,"PHASE1":315,"PHASE2":317,"PHASE3":319,"PHASE4":321,"NA":323},{"trials":314,"activeCount":98},[],{"trials":316,"activeCount":98},[],{"trials":318,"activeCount":98},[],{"trials":320,"activeCount":98},[],{"trials":322,"activeCount":98},[],{"trials":324,"activeCount":94,"soonestReadout":213},[325],{"nctId":326,"briefTitle":327,"status":106,"phases":328,"primaryCompletion":213,"completion":329,"start":330,"enrollment":331,"conditions":332,"interventions":334},"NCT06015256","Characterization of Natural Killer Cells in Severe Asthma Patients in Comparison With Control Subjects",[91],"2030-09","2023-09-07",448,[333],"Asthma Acute",[311],{"intervention":59,"totalTrials":94,"cells":336},{"EARLY_PHASE1":337,"PHASE1":339,"PHASE2":341,"PHASE3":343,"PHASE4":345,"NA":347},{"trials":338,"activeCount":98},[],{"trials":340,"activeCount":98},[],{"trials":342,"activeCount":98},[],{"trials":344,"activeCount":98},[],{"trials":346,"activeCount":98},[],{"trials":348,"activeCount":94,"soonestReadout":58},[349],{"nctId":56,"briefTitle":57,"status":106,"phases":350,"primaryCompletion":58,"completion":351,"start":352,"enrollment":353,"conditions":354,"interventions":359},[],"2027-01-12","2021-08-12",16,[355,356,357,358],"Immune Deficiency","Autoimmune Diseases","Infections","Diagnosis",[59],{"intervention":39,"totalTrials":94,"cells":361},{"EARLY_PHASE1":362,"PHASE1":364,"PHASE2":366,"PHASE3":368,"PHASE4":370,"NA":372},{"trials":363,"activeCount":98},[],{"trials":365,"activeCount":98},[],{"trials":367,"activeCount":98},[],{"trials":369,"activeCount":98},[],{"trials":371,"activeCount":98},[],{"trials":373,"activeCount":94,"soonestReadout":38},[374],{"nctId":36,"briefTitle":37,"status":163,"phases":375,"primaryCompletion":38,"completion":376,"start":377,"enrollment":378,"conditions":379,"interventions":381},[],"2031-03-31","2021-03-31",10250,[380],"Genetics, Population",[39],{"intervention":383,"totalTrials":94,"cells":384},"Blood sample collection; gastrointestinal biopsy",{"EARLY_PHASE1":385,"PHASE1":387,"PHASE2":389,"PHASE3":391,"PHASE4":393,"NA":395},{"trials":386,"activeCount":98},[],{"trials":388,"activeCount":98},[],{"trials":390,"activeCount":98},[],{"trials":392,"activeCount":98},[],{"trials":394,"activeCount":98},[],{"trials":396,"activeCount":94,"soonestReadout":401},[397],{"nctId":398,"briefTitle":399,"status":106,"phases":400,"primaryCompletion":401,"completion":402,"start":403,"enrollment":404,"conditions":405,"interventions":409},"NCT04280510","Pathogenic Study of Adult Immune Enteropathies",[],"2030-02-27","2033-02-27","2020-02-27",200,[406,407,408],"Celiac Disease","Autoimmune Enteropathy","Inflammatory Bowel Diseases",[383],{"intervention":49,"totalTrials":94,"cells":411},{"EARLY_PHASE1":412,"PHASE1":414,"PHASE2":416,"PHASE3":418,"PHASE4":420,"NA":422},{"trials":413,"activeCount":98},[],{"trials":415,"activeCount":98},[],{"trials":417,"activeCount":98},[],{"trials":419,"activeCount":98},[],{"trials":421,"activeCount":98},[],{"trials":423,"activeCount":94,"soonestReadout":48},[424],{"nctId":46,"briefTitle":47,"status":106,"phases":425,"primaryCompletion":48,"completion":426,"start":427,"enrollment":428,"conditions":429,"interventions":434},[91],"2026-06-26","2022-09-26",400,[430,431,432,433],"Infertility","Intellectual Disability","Malformation","Miscarriage",[49,435],"Longread sequencing",{"intervention":435,"totalTrials":94,"cells":437},{"EARLY_PHASE1":438,"PHASE1":440,"PHASE2":442,"PHASE3":444,"PHASE4":446,"NA":448},{"trials":439,"activeCount":98},[],{"trials":441,"activeCount":98},[],{"trials":443,"activeCount":98},[],{"trials":445,"activeCount":98},[],{"trials":447,"activeCount":98},[],{"trials":449,"activeCount":94,"soonestReadout":48},[450],{"nctId":46,"briefTitle":47,"status":106,"phases":451,"primaryCompletion":48,"completion":426,"start":427,"enrollment":428,"conditions":452,"interventions":453},[91],[430,431,432,433],[49,435],{"intervention":455,"totalTrials":94,"cells":456},"DNA from subjects will be stored in the biobank of our study.",{"EARLY_PHASE1":457,"PHASE1":459,"PHASE2":461,"PHASE3":463,"PHASE4":465,"NA":467},{"trials":458,"activeCount":98},[],{"trials":460,"activeCount":98},[],{"trials":462,"activeCount":98},[],{"trials":464,"activeCount":98},[],{"trials":466,"activeCount":98},[],{"trials":468,"activeCount":94,"soonestReadout":473},[469],{"nctId":470,"briefTitle":471,"status":106,"phases":472,"primaryCompletion":473,"completion":473,"start":474,"enrollment":475,"conditions":476,"interventions":478},"NCT04727489","Study of the Genetic Factors Involved in Autism and Related Disorders",[],"2036-03","2021-03-30",3800,[477],"Autism Spectrum Disorder",[455],{"intervention":69,"totalTrials":94,"cells":480},{"EARLY_PHASE1":481,"PHASE1":483,"PHASE2":485,"PHASE3":487,"PHASE4":489,"NA":491},{"trials":482,"activeCount":98},[],{"trials":484,"activeCount":98},[],{"trials":486,"activeCount":98},[],{"trials":488,"activeCount":98},[],{"trials":490,"activeCount":98},[],{"trials":492,"activeCount":94,"soonestReadout":68},[493],{"nctId":66,"briefTitle":67,"status":106,"phases":494,"primaryCompletion":68,"completion":68,"start":495,"enrollment":496,"conditions":497,"interventions":499},[],"2021-10-07",70,[498],"Kidney Transplant Rejection",[69],{"intervention":54,"totalTrials":94,"cells":501},{"EARLY_PHASE1":502,"PHASE1":504,"PHASE2":506,"PHASE3":508,"PHASE4":510,"NA":512},{"trials":503,"activeCount":98},[],{"trials":505,"activeCount":98},[],{"trials":507,"activeCount":98},[],{"trials":509,"activeCount":98},[],{"trials":511,"activeCount":98},[],{"trials":513,"activeCount":94,"soonestReadout":53},[514],{"nctId":51,"briefTitle":52,"status":106,"phases":515,"primaryCompletion":53,"completion":516,"start":517,"enrollment":518,"conditions":519,"interventions":539},[],"2026-06","2021-09-07",500,[520,521,356,522,523,524,525,526,527,528,529,530,531,532,533,534,535,536,537,538],"Autoimmune Lymphoproliferative Syndrome","Autoimmune Cytopenia","Autoimmune Anemia","Autoimmune Thrombocytopenia","Autoimmune Hepatitis","Autoimmune Diabetes","Autoimmune Rheumatologic Disease","Systemic Lupus Erythematosus","Juvenile Idiopathic Arthritis","Hemophagocytic Lymphohistiocytoses","EBV Lymphoproliferation","RAS-Associated Autoimmune Leucoproliferative Disease","Primary Immunodeficiency","APECED","IPEX","BENTA","Enteropathy, Autoimmune","Combined Immunodeficiency","IBD",[54],{"intervention":299,"totalTrials":94,"cells":541},{"EARLY_PHASE1":542,"PHASE1":544,"PHASE2":546,"PHASE3":548,"PHASE4":550,"NA":552},{"trials":543,"activeCount":98},[],{"trials":545,"activeCount":98},[],{"trials":547,"activeCount":98},[],{"trials":549,"activeCount":98},[],{"trials":551,"activeCount":98},[],{"trials":553,"activeCount":94,"soonestReadout":291},[554],{"nctId":288,"briefTitle":289,"status":106,"phases":555,"primaryCompletion":291,"completion":291,"start":292,"enrollment":293,"conditions":556,"interventions":557},[91],[295,296,297],[273,299],{"intervention":74,"totalTrials":94,"cells":559},{"EARLY_PHASE1":560,"PHASE1":562,"PHASE2":564,"PHASE3":566,"PHASE4":568,"NA":570},{"trials":561,"activeCount":98},[],{"trials":563,"activeCount":98},[],{"trials":565,"activeCount":98},[],{"trials":567,"activeCount":98},[],{"trials":569,"activeCount":98},[],{"trials":571,"activeCount":94,"soonestReadout":73},[572],{"nctId":71,"briefTitle":72,"status":106,"phases":573,"primaryCompletion":73,"completion":574,"start":575,"enrollment":576,"conditions":577,"interventions":579},[91],"2028-03-25","2025-03-25",50,[578],"Developmental Language Disorder",[74],{"intervention":581,"totalTrials":94,"cells":582},"Anti-H1N1v Vaccine",{"EARLY_PHASE1":583,"PHASE1":585,"PHASE2":587,"PHASE3":589,"PHASE4":591,"NA":604},{"trials":584,"activeCount":98},[],{"trials":586,"activeCount":98},[],{"trials":588,"activeCount":98},[],{"trials":590,"activeCount":98},[],{"trials":592,"activeCount":98},[593],{"nctId":594,"briefTitle":595,"status":246,"phases":596,"primaryCompletion":597,"completion":598,"start":599,"enrollment":600,"conditions":601,"interventions":603},"NCT01063608","Study of Immune Responses After Vaccination Against Seasonal Influenza Virus and Against Influenza H1N1-v Pandemic Virus in a Medical Staff.",[90],"2009-12","2010-05","2009-10",147,[602],"Influenza A Virus, H1N1 Subtype",[581],{"trials":605,"activeCount":98},[],{"intervention":607,"totalTrials":94,"cells":608},"Venlafaxine extended release",{"EARLY_PHASE1":609,"PHASE1":611,"PHASE2":613,"PHASE3":615,"PHASE4":617,"NA":630},{"trials":610,"activeCount":98},[],{"trials":612,"activeCount":98},[],{"trials":614,"activeCount":98},[],{"trials":616,"activeCount":98},[],{"trials":618,"activeCount":98},[619],{"nctId":620,"briefTitle":621,"status":246,"phases":622,"primaryCompletion":623,"completion":623,"start":624,"enrollment":625,"conditions":626,"interventions":629},"NCT02051413","Beta-arrestins and Response to Venlafaxine in Major Depressive Disorder (MDD) (DEPARRESTCLIN)",[90],"2018-05","2014-02-18",67,[627,628],"Major Depressive Disorder","Major Depressive Episode",[607],{"trials":631,"activeCount":98},[],{"intervention":633,"totalTrials":94,"cells":634},"Nilotinib",{"EARLY_PHASE1":635,"PHASE1":637,"PHASE2":639,"PHASE3":641,"PHASE4":663,"NA":665},{"trials":636,"activeCount":98},[],{"trials":638,"activeCount":98},[],{"trials":640,"activeCount":98},[],{"trials":642,"activeCount":98},[643],{"nctId":644,"briefTitle":645,"status":246,"phases":646,"primaryCompletion":647,"completion":648,"start":649,"enrollment":650,"conditions":651,"interventions":653},"NCT03784014","Molecular Profiling of Advanced Soft-tissue Sarcomas",[89],"2023-12-01","2026-01-20","2019-10-19",603,[652],"Soft Tissue Sarcoma",[633,654,655,656,657,658,659,660,661,662],"Ceritinib","Capmatinib","Lapatinib","Trametinib","Trametinib and Dabrafenib","Olaparib and Durvalumab","Palbociclib","Glasdegib","TAS-120",{"trials":664,"activeCount":98},[],{"trials":666,"activeCount":98},[],{"intervention":654,"totalTrials":94,"cells":668},{"EARLY_PHASE1":669,"PHASE1":671,"PHASE2":673,"PHASE3":675,"PHASE4":681,"NA":683},{"trials":670,"activeCount":98},[],{"trials":672,"activeCount":98},[],{"trials":674,"activeCount":98},[],{"trials":676,"activeCount":98},[677],{"nctId":644,"briefTitle":645,"status":246,"phases":678,"primaryCompletion":647,"completion":648,"start":649,"enrollment":650,"conditions":679,"interventions":680},[89],[652],[633,654,655,656,657,658,659,660,661,662],{"trials":682,"activeCount":98},[],{"trials":684,"activeCount":98},[],{"intervention":655,"totalTrials":94,"cells":686},{"EARLY_PHASE1":687,"PHASE1":689,"PHASE2":691,"PHASE3":693,"PHASE4":699,"NA":701},{"trials":688,"activeCount":98},[],{"trials":690,"activeCount":98},[],{"trials":692,"activeCount":98},[],{"trials":694,"activeCount":98},[695],{"nctId":644,"briefTitle":645,"status":246,"phases":696,"primaryCompletion":647,"completion":648,"start":649,"enrollment":650,"conditions":697,"interventions":698},[89],[652],[633,654,655,656,657,658,659,660,661,662],{"trials":700,"activeCount":98},[],{"trials":702,"activeCount":98},[],{"intervention":656,"totalTrials":94,"cells":704},{"EARLY_PHASE1":705,"PHASE1":707,"PHASE2":709,"PHASE3":711,"PHASE4":717,"NA":719},{"trials":706,"activeCount":98},[],{"trials":708,"activeCount":98},[],{"trials":710,"activeCount":98},[],{"trials":712,"activeCount":98},[713],{"nctId":644,"briefTitle":645,"status":246,"phases":714,"primaryCompletion":647,"completion":648,"start":649,"enrollment":650,"conditions":715,"interventions":716},[89],[652],[633,654,655,656,657,658,659,660,661,662],{"trials":718,"activeCount":98},[],{"trials":720,"activeCount":98},[],{"intervention":657,"totalTrials":94,"cells":722},{"EARLY_PHASE1":723,"PHASE1":725,"PHASE2":727,"PHASE3":729,"PHASE4":735,"NA":737},{"trials":724,"activeCount":98},[],{"trials":726,"activeCount":98},[],{"trials":728,"activeCount":98},[],{"trials":730,"activeCount":98},[731],{"nctId":644,"briefTitle":645,"status":246,"phases":732,"primaryCompletion":647,"completion":648,"start":649,"enrollment":650,"conditions":733,"interventions":734},[89],[652],[633,654,655,656,657,658,659,660,661,662],{"trials":736,"activeCount":98},[],{"trials":738,"activeCount":98},[],{"intervention":658,"totalTrials":94,"cells":740},{"EARLY_PHASE1":741,"PHASE1":743,"PHASE2":745,"PHASE3":747,"PHASE4":753,"NA":755},{"trials":742,"activeCount":98},[],{"trials":744,"activeCount":98},[],{"trials":746,"activeCount":98},[],{"trials":748,"activeCount":98},[749],{"nctId":644,"briefTitle":645,"status":246,"phases":750,"primaryCompletion":647,"completion":648,"start":649,"enrollment":650,"conditions":751,"interventions":752},[89],[652],[633,654,655,656,657,658,659,660,661,662],{"trials":754,"activeCount":98},[],{"trials":756,"activeCount":98},[],{"intervention":659,"totalTrials":94,"cells":758},{"EARLY_PHASE1":759,"PHASE1":761,"PHASE2":763,"PHASE3":765,"PHASE4":771,"NA":773},{"trials":760,"activeCount":98},[],{"trials":762,"activeCount":98},[],{"trials":764,"activeCount":98},[],{"trials":766,"activeCount":98},[767],{"nctId":644,"briefTitle":645,"status":246,"phases":768,"primaryCompletion":647,"completion":648,"start":649,"enrollment":650,"conditions":769,"interventions":770},[89],[652],[633,654,655,656,657,658,659,660,661,662],{"trials":772,"activeCount":98},[],{"trials":774,"activeCount":98},[],{"intervention":660,"totalTrials":94,"cells":776},{"EARLY_PHASE1":777,"PHASE1":779,"PHASE2":781,"PHASE3":783,"PHASE4":789,"NA":791},{"trials":778,"activeCount":98},[],{"trials":780,"activeCount":98},[],{"trials":782,"activeCount":98},[],{"trials":784,"activeCount":98},[785],{"nctId":644,"briefTitle":645,"status":246,"phases":786,"primaryCompletion":647,"completion":648,"start":649,"enrollment":650,"conditions":787,"interventions":788},[89],[652],[633,654,655,656,657,658,659,660,661,662],{"trials":790,"activeCount":98},[],{"trials":792,"activeCount":98},[],{"intervention":661,"totalTrials":94,"cells":794},{"EARLY_PHASE1":795,"PHASE1":797,"PHASE2":799,"PHASE3":801,"PHASE4":807,"NA":809},{"trials":796,"activeCount":98},[],{"trials":798,"activeCount":98},[],{"trials":800,"activeCount":98},[],{"trials":802,"activeCount":98},[803],{"nctId":644,"briefTitle":645,"status":246,"phases":804,"primaryCompletion":647,"completion":648,"start":649,"enrollment":650,"conditions":805,"interventions":806},[89],[652],[633,654,655,656,657,658,659,660,661,662],{"trials":808,"activeCount":98},[],{"trials":810,"activeCount":98},[],{"intervention":662,"totalTrials":94,"cells":812},{"EARLY_PHASE1":813,"PHASE1":815,"PHASE2":817,"PHASE3":819,"PHASE4":825,"NA":827},{"trials":814,"activeCount":98},[],{"trials":816,"activeCount":98},[],{"trials":818,"activeCount":98},[],{"trials":820,"activeCount":98},[821],{"nctId":644,"briefTitle":645,"status":246,"phases":822,"primaryCompletion":647,"completion":648,"start":649,"enrollment":650,"conditions":823,"interventions":824},[89],[652],[633,654,655,656,657,658,659,660,661,662],{"trials":826,"activeCount":98},[],{"trials":828,"activeCount":98},[],{"intervention":830,"totalTrials":94,"cells":831},"Bilhvax vaccine",{"EARLY_PHASE1":832,"PHASE1":834,"PHASE2":836,"PHASE3":838,"PHASE4":852,"NA":854},{"trials":833,"activeCount":98},[],{"trials":835,"activeCount":98},[],{"trials":837,"activeCount":98},[],{"trials":839,"activeCount":98},[840],{"nctId":841,"briefTitle":842,"status":246,"phases":843,"primaryCompletion":844,"completion":845,"start":846,"enrollment":847,"conditions":848,"interventions":851},"NCT00870649","Efficacy of Bilhvax in Association With Praziquantel for Prevention of Clinical Recurrences of Schistosoma Haematobium",[89],"2012-06","2012-12","2009-02",250,[849,850],"Urinary Schistosomiasis","Schistosoma Haematobium",[830],{"trials":853,"activeCount":98},[],{"trials":855,"activeCount":98},[],{"intervention":857,"totalTrials":94,"cells":858},"Anakinra",{"EARLY_PHASE1":859,"PHASE1":861,"PHASE2":863,"PHASE3":865,"PHASE4":878,"NA":880},{"trials":860,"activeCount":98},[],{"trials":862,"activeCount":98},[],{"trials":864,"activeCount":98},[],{"trials":866,"activeCount":98},[867],{"nctId":868,"briefTitle":869,"status":246,"phases":870,"primaryCompletion":871,"completion":871,"start":872,"enrollment":873,"conditions":874,"interventions":876},"NCT00339157","Interleukin-1 Receptor Antagonist (IL-1RA) (ANAKINRA) IN SEVERE SYSTEMIC-ONSET JUVENILE IDIOPATHIC ARTHRITIS",[88,89],"2008-06-10","2006-05-11",24,[875],"Systemic-Onset Juvenile Idiopathic Arthritis",[857,877],"Pneumo23",{"trials":879,"activeCount":98},[],{"trials":881,"activeCount":98},[],{"intervention":877,"totalTrials":94,"cells":883},{"EARLY_PHASE1":884,"PHASE1":886,"PHASE2":888,"PHASE3":890,"PHASE4":896,"NA":898},{"trials":885,"activeCount":98},[],{"trials":887,"activeCount":98},[],{"trials":889,"activeCount":98},[],{"trials":891,"activeCount":98},[892],{"nctId":868,"briefTitle":869,"status":246,"phases":893,"primaryCompletion":871,"completion":871,"start":872,"enrollment":873,"conditions":894,"interventions":895},[88,89],[875],[857,877],{"trials":897,"activeCount":98},[],{"trials":899,"activeCount":98},[],{"intervention":901,"totalTrials":94,"cells":902},"Fluconazole",{"EARLY_PHASE1":903,"PHASE1":905,"PHASE2":907,"PHASE3":909,"PHASE4":922,"NA":924},{"trials":904,"activeCount":98},[],{"trials":906,"activeCount":98},[],{"trials":908,"activeCount":98},[],{"trials":910,"activeCount":98},[911],{"nctId":912,"briefTitle":913,"status":246,"phases":914,"primaryCompletion":915,"completion":915,"start":916,"enrollment":917,"conditions":918,"interventions":920},"NCT02145832","Fluconazole Versus Micafungin in Neonates With Candidiasis",[88,89],"2015-11","2014-10",100,[919],"Candidiasis",[901,921],"Micafungin",{"trials":923,"activeCount":98},[],{"trials":925,"activeCount":98},[],{"intervention":921,"totalTrials":94,"cells":927},{"EARLY_PHASE1":928,"PHASE1":930,"PHASE2":932,"PHASE3":934,"PHASE4":940,"NA":942},{"trials":929,"activeCount":98},[],{"trials":931,"activeCount":98},[],{"trials":933,"activeCount":98},[],{"trials":935,"activeCount":98},[936],{"nctId":912,"briefTitle":913,"status":246,"phases":937,"primaryCompletion":915,"completion":915,"start":916,"enrollment":917,"conditions":938,"interventions":939},[88,89],[919],[901,921],{"trials":941,"activeCount":98},[],{"trials":943,"activeCount":98},[],{"intervention":945,"totalTrials":94,"cells":946},"risedronate",{"EARLY_PHASE1":947,"PHASE1":949,"PHASE2":951,"PHASE3":953,"PHASE4":966,"NA":968},{"trials":948,"activeCount":98},[],{"trials":950,"activeCount":98},[],{"trials":952,"activeCount":98},[],{"trials":954,"activeCount":98},[955],{"nctId":956,"briefTitle":957,"status":246,"phases":958,"primaryCompletion":959,"completion":960,"start":961,"enrollment":962,"conditions":963,"interventions":965},"NCT00445575","Effect of Risedronate on Bone Morbidity in Fibrous Dysplasia of Bone",[88,89],"2017-12","2017-12-07","2007-07-22",80,[964],"Fibrous Dysplasia of Bone",[945,945],{"trials":967,"activeCount":98},[],{"trials":969,"activeCount":98},[],{"intervention":971,"totalTrials":94,"cells":972},"leuprorelin",{"EARLY_PHASE1":973,"PHASE1":975,"PHASE2":977,"PHASE3":979,"PHASE4":992,"NA":994},{"trials":974,"activeCount":98},[],{"trials":976,"activeCount":98},[],{"trials":978,"activeCount":98},[],{"trials":980,"activeCount":98},[981],{"nctId":982,"briefTitle":983,"status":258,"phases":984,"primaryCompletion":985,"completion":985,"start":986,"enrollment":987,"conditions":988,"interventions":990},"NCT00601276","Comparison of Two Pharmacological Treatments of Pedophilia",[89],"2009-06","2007-12",48,[989],"Pedophilia",[971,991],"Cyproterone acetate",{"trials":993,"activeCount":98},[],{"trials":995,"activeCount":98},[],{"intervention":991,"totalTrials":94,"cells":997},{"EARLY_PHASE1":998,"PHASE1":1000,"PHASE2":1002,"PHASE3":1004,"PHASE4":1010,"NA":1012},{"trials":999,"activeCount":98},[],{"trials":1001,"activeCount":98},[],{"trials":1003,"activeCount":98},[],{"trials":1005,"activeCount":98},[1006],{"nctId":982,"briefTitle":983,"status":258,"phases":1007,"primaryCompletion":985,"completion":985,"start":986,"enrollment":987,"conditions":1008,"interventions":1009},[89],[989],[971,991],{"trials":1011,"activeCount":98},[],{"trials":1013,"activeCount":98},[],{"intervention":1015,"totalTrials":94,"cells":1016},"Remdesivir",{"EARLY_PHASE1":1017,"PHASE1":1019,"PHASE2":1021,"PHASE3":1023,"PHASE4":1040,"NA":1042},{"trials":1018,"activeCount":98},[],{"trials":1020,"activeCount":98},[],{"trials":1022,"activeCount":98},[],{"trials":1024,"activeCount":98},[1025],{"nctId":1026,"briefTitle":1027,"status":246,"phases":1028,"primaryCompletion":1029,"completion":1030,"start":1031,"enrollment":1032,"conditions":1033,"interventions":1035},"NCT04315948","Trial of Treatments for COVID-19 in Hospitalized Adults",[89],"2022-07-09","2023-09-25","2020-03-22",1552,[1034],"Corona Virus Infection",[1015,1036,1037,1038,1039],"Lopinavir\u002Fritonavir","Interferon Beta-1A","Hydroxychloroquine","AZD7442",{"trials":1041,"activeCount":98},[],{"trials":1043,"activeCount":98},[],{"intervention":1036,"totalTrials":94,"cells":1045},{"EARLY_PHASE1":1046,"PHASE1":1048,"PHASE2":1050,"PHASE3":1052,"PHASE4":1058,"NA":1060},{"trials":1047,"activeCount":98},[],{"trials":1049,"activeCount":98},[],{"trials":1051,"activeCount":98},[],{"trials":1053,"activeCount":98},[1054],{"nctId":1026,"briefTitle":1027,"status":246,"phases":1055,"primaryCompletion":1029,"completion":1030,"start":1031,"enrollment":1032,"conditions":1056,"interventions":1057},[89],[1034],[1015,1036,1037,1038,1039],{"trials":1059,"activeCount":98},[],{"trials":1061,"activeCount":98},[],{"intervention":1037,"totalTrials":94,"cells":1063},{"EARLY_PHASE1":1064,"PHASE1":1066,"PHASE2":1068,"PHASE3":1070,"PHASE4":1076,"NA":1078},{"trials":1065,"activeCount":98},[],{"trials":1067,"activeCount":98},[],{"trials":1069,"activeCount":98},[],{"trials":1071,"activeCount":98},[1072],{"nctId":1026,"briefTitle":1027,"status":246,"phases":1073,"primaryCompletion":1029,"completion":1030,"start":1031,"enrollment":1032,"conditions":1074,"interventions":1075},[89],[1034],[1015,1036,1037,1038,1039],{"trials":1077,"activeCount":98},[],{"trials":1079,"activeCount":98},[],{"intervention":1038,"totalTrials":94,"cells":1081},{"EARLY_PHASE1":1082,"PHASE1":1084,"PHASE2":1086,"PHASE3":1088,"PHASE4":1094,"NA":1096},{"trials":1083,"activeCount":98},[],{"trials":1085,"activeCount":98},[],{"trials":1087,"activeCount":98},[],{"trials":1089,"activeCount":98},[1090],{"nctId":1026,"briefTitle":1027,"status":246,"phases":1091,"primaryCompletion":1029,"completion":1030,"start":1031,"enrollment":1032,"conditions":1092,"interventions":1093},[89],[1034],[1015,1036,1037,1038,1039],{"trials":1095,"activeCount":98},[],{"trials":1097,"activeCount":98},[],{"intervention":1039,"totalTrials":94,"cells":1099},{"EARLY_PHASE1":1100,"PHASE1":1102,"PHASE2":1104,"PHASE3":1106,"PHASE4":1112,"NA":1114},{"trials":1101,"activeCount":98},[],{"trials":1103,"activeCount":98},[],{"trials":1105,"activeCount":98},[],{"trials":1107,"activeCount":98},[1108],{"nctId":1026,"briefTitle":1027,"status":246,"phases":1109,"primaryCompletion":1029,"completion":1030,"start":1031,"enrollment":1032,"conditions":1110,"interventions":1111},[89],[1034],[1015,1036,1037,1038,1039],{"trials":1113,"activeCount":98},[],{"trials":1115,"activeCount":98},[],{"intervention":1117,"totalTrials":94,"cells":1118},"Rapamycin",{"EARLY_PHASE1":1119,"PHASE1":1121,"PHASE2":1123,"PHASE3":1125,"PHASE4":1137,"NA":1139},{"trials":1120,"activeCount":98},[],{"trials":1122,"activeCount":98},[],{"trials":1124,"activeCount":98},[],{"trials":1126,"activeCount":98},[1127],{"nctId":1128,"briefTitle":1129,"status":246,"phases":1130,"primaryCompletion":1131,"completion":1131,"start":1132,"enrollment":1133,"conditions":1134,"interventions":1136},"NCT02481453","Rapamycine vs Placebo for the Treatment of Inclusion Body Myositis",[88,89],"2018-01-22","2015-07-15",44,[1135],"Inclusion Body Myositis (IBM)",[1117],{"trials":1138,"activeCount":98},[],{"trials":1140,"activeCount":98},[],{"intervention":1142,"totalTrials":94,"cells":1143},"Prostaglandin E2",{"EARLY_PHASE1":1144,"PHASE1":1146,"PHASE2":1148,"PHASE3":1150,"PHASE4":1163,"NA":1165},{"trials":1145,"activeCount":98},[],{"trials":1147,"activeCount":98},[],{"trials":1149,"activeCount":98},[],{"trials":1151,"activeCount":98},[1152],{"nctId":1153,"briefTitle":1154,"status":1155,"phases":1156,"primaryCompletion":1157,"completion":1157,"start":1158,"enrollment":98,"conditions":1159,"interventions":1162},"NCT00545194","Cervical Ripening Before Induction of Labour at Term: a Randomised Comparison of Prostin vs Propess","WITHDRAWN",[89],"2004-10","2002-01",[1160,1161],"Cervical Ripening","Labor, Induced",[1142],{"trials":1164,"activeCount":98},[],{"trials":1166,"activeCount":98},[],{"intervention":1168,"totalTrials":94,"cells":1169},"Azithromycin",{"EARLY_PHASE1":1170,"PHASE1":1172,"PHASE2":1174,"PHASE3":1176,"PHASE4":1188,"NA":1190},{"trials":1171,"activeCount":98},[],{"trials":1173,"activeCount":98},[],{"trials":1175,"activeCount":98},[],{"trials":1177,"activeCount":98},[1178],{"nctId":1179,"briefTitle":1180,"status":1155,"phases":1181,"primaryCompletion":1182,"completion":1183,"start":1184,"enrollment":98,"conditions":1185,"interventions":1187},"NCT02282176","TINN2: Treat Infection in NeoNates 2",[89],"2017-01","2018-01","2015-01",[1186],"Bronchopulmonary Dysplasia",[1168],{"trials":1189,"activeCount":98},[],{"trials":1191,"activeCount":98},[],{"intervention":1193,"totalTrials":94,"cells":1194},"Acetaminophen",{"EARLY_PHASE1":1195,"PHASE1":1197,"PHASE2":1199,"PHASE3":1201,"PHASE4":1215,"NA":1217},{"trials":1196,"activeCount":98},[],{"trials":1198,"activeCount":98},[],{"trials":1200,"activeCount":98},[],{"trials":1202,"activeCount":98},[1203],{"nctId":1204,"briefTitle":1205,"status":246,"phases":1206,"primaryCompletion":1207,"completion":1207,"start":1208,"enrollment":1209,"conditions":1210,"interventions":1213},"NCT04459117","Prophylactic Treatment of the Ductus Arteriosus in Preterm Infants by Acetaminophen",[88,89],"2024-06-20","2020-10-29",804,[1211,1193,1212],"Patency of the Ductus Arteriosus","Extreme Prematurity",[1193,1214],"NACL 0.9%",{"trials":1216,"activeCount":98},[],{"trials":1218,"activeCount":98},[],{"intervention":1214,"totalTrials":94,"cells":1220},{"EARLY_PHASE1":1221,"PHASE1":1223,"PHASE2":1225,"PHASE3":1227,"PHASE4":1233,"NA":1235},{"trials":1222,"activeCount":98},[],{"trials":1224,"activeCount":98},[],{"trials":1226,"activeCount":98},[],{"trials":1228,"activeCount":98},[1229],{"nctId":1204,"briefTitle":1205,"status":246,"phases":1230,"primaryCompletion":1207,"completion":1207,"start":1208,"enrollment":1209,"conditions":1231,"interventions":1232},[88,89],[1211,1193,1212],[1193,1214],{"trials":1234,"activeCount":98},[],{"trials":1236,"activeCount":98},[],{"intervention":1238,"totalTrials":94,"cells":1239},"perindopril",{"EARLY_PHASE1":1240,"PHASE1":1242,"PHASE2":1244,"PHASE3":1246,"PHASE4":1257,"NA":1259},{"trials":1241,"activeCount":98},[],{"trials":1243,"activeCount":98},[],{"trials":1245,"activeCount":98},[],{"trials":1247,"activeCount":98},[1248],{"nctId":1249,"briefTitle":1250,"status":258,"phases":1251,"primaryCompletion":305,"completion":305,"start":1252,"enrollment":1253,"conditions":1254,"interventions":1256},"NCT01583114","PREclinical Mutation CARriers From Families With DIlated Cardiomyopathy and ACE Inhibitors",[89],"2011-12",6,[1255],"Dilated Cardiomyopathy",[1238],{"trials":1258,"activeCount":98},[],{"trials":1260,"activeCount":98},[],{"intervention":1262,"totalTrials":262,"cells":1263},"Triheptanoin",{"EARLY_PHASE1":1264,"PHASE1":1266,"PHASE2":1268,"PHASE3":1290,"PHASE4":1292,"NA":1294},{"trials":1265,"activeCount":98},[],{"trials":1267,"activeCount":98},[],{"trials":1269,"activeCount":98},[1270,1280],{"nctId":1271,"briefTitle":1272,"status":246,"phases":1273,"primaryCompletion":1274,"completion":1274,"start":1275,"enrollment":1276,"conditions":1277,"interventions":1279},"NCT02408354","Pilot Study, Comparative, Single-center, Randomized, Crossover, Double-blind, Against Placebo, Testing the Effectiveness of Triheptanoin Oil in Alternating Hemiplegia of Childhood",[88],"2017-04-05","2015-03-25",10,[1278],"Alternating Hemiplegia of Childhood",[1262],{"nctId":1281,"briefTitle":1282,"status":246,"phases":1283,"primaryCompletion":1284,"completion":1284,"start":1285,"enrollment":1286,"conditions":1287,"interventions":1289},"NCT02919631","Triheptanoin in Mc Ardle",[88],"2017-06-26","2016-11-16",12,[1288],"Glycogen Storage Disease Type V",[1262],{"trials":1291,"activeCount":98},[],{"trials":1293,"activeCount":98},[],{"trials":1295,"activeCount":98},[],{"intervention":1297,"totalTrials":94,"cells":1298},"Artesunate Oral Product",{"EARLY_PHASE1":1299,"PHASE1":1301,"PHASE2":1303,"PHASE3":1314,"PHASE4":1316,"NA":1318},{"trials":1300,"activeCount":98},[],{"trials":1302,"activeCount":98},[],{"trials":1304,"activeCount":98},[1305],{"nctId":1306,"briefTitle":1307,"status":246,"phases":1308,"primaryCompletion":1309,"completion":1309,"start":1310,"enrollment":306,"conditions":1311,"interventions":1313},"NCT04921930","Evaluation of the Effect of Artesunate in Friedreich Ataxia (FA)",[87,88],"2024-04-17","2022-05-06",[1312],"Friedreich Ataxia",[1297],{"trials":1315,"activeCount":98},[],{"trials":1317,"activeCount":98},[],{"trials":1319,"activeCount":98},[],{"intervention":1321,"totalTrials":94,"cells":1322},"intracerebral administration of AAVrh.10cuARSA",{"EARLY_PHASE1":1323,"PHASE1":1325,"PHASE2":1327,"PHASE3":1339,"PHASE4":1341,"NA":1343},{"trials":1324,"activeCount":98},[],{"trials":1326,"activeCount":98},[],{"trials":1328,"activeCount":98},[1329],{"nctId":1330,"briefTitle":1331,"status":246,"phases":1332,"primaryCompletion":1333,"completion":1334,"start":1335,"enrollment":29,"conditions":1336,"interventions":1338},"NCT01801709","Intracerebral Gene Therapy for Children With Early Onset Forms of Metachromatic Leukodystrophy",[87,88],"2016-06","2022-12-20","2014-06",[1337],"Metachromatic Leukodystrophy",[1321],{"trials":1340,"activeCount":98},[],{"trials":1342,"activeCount":98},[],{"trials":1344,"activeCount":98},[],{"intervention":1346,"totalTrials":94,"cells":1347},"GLUT1 DS",{"EARLY_PHASE1":1348,"PHASE1":1350,"PHASE2":1352,"PHASE3":1363,"PHASE4":1365,"NA":1367},{"trials":1349,"activeCount":98},[],{"trials":1351,"activeCount":98},[],{"trials":1353,"activeCount":98},[1354],{"nctId":1355,"briefTitle":1356,"status":246,"phases":1357,"primaryCompletion":1358,"completion":1358,"start":1359,"enrollment":306,"conditions":1360,"interventions":1362},"NCT02014883","Phase II Open Label Study Using Triheptanoin in Patients With Glucose Type 1 Transporter Deficiency GLUT1-DS",[88],"2019-07-04","2013-12-04",[1361],"Glut1 Deficiency Syndrome",[1346],{"trials":1364,"activeCount":98},[],{"trials":1366,"activeCount":98},[],{"trials":1368,"activeCount":98},[],{"intervention":1370,"totalTrials":94,"cells":1371},"sitaxentan",{"EARLY_PHASE1":1372,"PHASE1":1374,"PHASE2":1376,"PHASE3":1388,"PHASE4":1390,"NA":1392},{"trials":1373,"activeCount":98},[],{"trials":1375,"activeCount":98},[],{"trials":1377,"activeCount":98},[1378],{"nctId":1379,"briefTitle":1380,"status":258,"phases":1381,"primaryCompletion":1382,"completion":1382,"start":1383,"enrollment":1384,"conditions":1385,"interventions":1387},"NCT01050491","Study on the Effects of Sitaxsentan on Airway Remodeling in Patients With Severe Asthma",[88],"2010-12","2009-11",17,[1386],"Effect of Sitaxsentan on Airway Remodeling in Severe Asthma",[1370],{"trials":1389,"activeCount":98},[],{"trials":1391,"activeCount":98},[],{"trials":1393,"activeCount":98},[],{"intervention":1395,"totalTrials":94,"cells":1396},"octreotide",{"EARLY_PHASE1":1397,"PHASE1":1399,"PHASE2":1401,"PHASE3":1414,"PHASE4":1416,"NA":1418},{"trials":1398,"activeCount":98},[],{"trials":1400,"activeCount":98},[],{"trials":1402,"activeCount":98},[1403],{"nctId":1404,"briefTitle":1405,"status":246,"phases":1406,"primaryCompletion":1407,"completion":1408,"start":1409,"enrollment":1410,"conditions":1411,"interventions":1413},"NCT00463983","Treatment of Idiopathic Pulmonary Fibrosis With Long Acting Octreotide",[87,88],"2010-01","2012-01","2006-10",25,[1412],"Idiopathic Pulmonary Fibrosis",[1395],{"trials":1415,"activeCount":98},[],{"trials":1417,"activeCount":98},[],{"trials":1419,"activeCount":98},[],{"intervention":1421,"totalTrials":94,"cells":1422},"Citalopram 30mg",{"EARLY_PHASE1":1423,"PHASE1":1425,"PHASE2":1427,"PHASE3":1437,"PHASE4":1439,"NA":1441},{"trials":1424,"activeCount":98},[],{"trials":1426,"activeCount":98},[],{"trials":1428,"activeCount":98},[1429],{"nctId":1430,"briefTitle":1431,"status":246,"phases":1432,"primaryCompletion":1335,"completion":1335,"start":1433,"enrollment":873,"conditions":1434,"interventions":1436},"NCT02113943","Double Blind Randomized, Monocentric, Cross-over, Placebo-controlled Study to Evaluate the Effect of Citalopram on Motivation",[88],"2014-04",[1435],"Normal Volunteers",[1421],{"trials":1438,"activeCount":98},[],{"trials":1440,"activeCount":98},[],{"trials":1442,"activeCount":98},[],{"intervention":1444,"totalTrials":94,"cells":1445},"Triheptanoin oil",{"EARLY_PHASE1":1446,"PHASE1":1448,"PHASE2":1450,"PHASE3":1460,"PHASE4":1462,"NA":1464},{"trials":1447,"activeCount":98},[],{"trials":1449,"activeCount":98},[],{"trials":1451,"activeCount":98},[1452],{"nctId":1453,"briefTitle":1454,"status":246,"phases":1455,"primaryCompletion":1456,"completion":1456,"start":1457,"enrollment":917,"conditions":1458,"interventions":1459},"NCT02453061","A Comparative Phase 2 Study Assessing the Efficacy of Triheptanoin, an Anaplerotic Therapy in Huntington's Disease",[88],"2019-12-03","2015-06-29",[25],[1444],{"trials":1461,"activeCount":98},[],{"trials":1463,"activeCount":98},[],{"trials":1465,"activeCount":98},[],{"intervention":1467,"totalTrials":94,"cells":1468},"99mTc-Annexin V-128 SPECT",{"EARLY_PHASE1":1469,"PHASE1":1471,"PHASE2":1473,"PHASE3":1485,"PHASE4":1487,"NA":1489},{"trials":1470,"activeCount":98},[],{"trials":1472,"activeCount":98},[],{"trials":1474,"activeCount":98},[1475],{"nctId":1476,"briefTitle":1477,"status":258,"phases":1478,"primaryCompletion":1479,"completion":1479,"start":1480,"enrollment":16,"conditions":1481,"interventions":1484},"NCT02459613","Assessment of Radiolabeled rhAnnexin V-128 in Infective Endocarditis",[87,88],"2017-05","2016-02-05",[1482,1483],"Endocarditis","Thrombosis",[1467],{"trials":1486,"activeCount":98},[],{"trials":1488,"activeCount":98},[],{"trials":1490,"activeCount":98},[],{"intervention":1492,"totalTrials":94,"cells":1493},"Non-adjuvanted A(H1N1)v influenza vaccine",{"EARLY_PHASE1":1494,"PHASE1":1496,"PHASE2":1498,"PHASE3":1508,"PHASE4":1510,"NA":1512},{"trials":1495,"activeCount":98},[],{"trials":1497,"activeCount":98},[],{"trials":1499,"activeCount":98},[1500],{"nctId":1501,"briefTitle":1502,"status":246,"phases":1503,"primaryCompletion":1407,"completion":1504,"start":1383,"enrollment":1505,"conditions":1506,"interventions":1507},"NCT01024400","Immunogenicity and Safety of an Inactivated Non-adjuvanted A(H1N1)v Influenza Vaccine in Pregnant Women",[88],"2010-07",110,[33],[1492],{"trials":1509,"activeCount":98},[],{"trials":1511,"activeCount":98},[],{"trials":1513,"activeCount":98},[],{"intervention":1515,"totalTrials":94,"cells":1516},"Xenbilox",{"EARLY_PHASE1":1517,"PHASE1":1519,"PHASE2":1521,"PHASE3":1534,"PHASE4":1536,"NA":1538},{"trials":1518,"activeCount":98},[],{"trials":1520,"activeCount":98},[],{"trials":1522,"activeCount":98},[1523],{"nctId":1524,"briefTitle":1525,"status":246,"phases":1526,"primaryCompletion":1527,"completion":1528,"start":1529,"enrollment":1286,"conditions":1530,"interventions":1532},"NCT02314208","Therapeutic Metabolic Intervention in Patients With Spastic Paraplegia SPG5",[88],"2017-09-27","2018-01-01","2015-01-08",[1531],"Spastic Paraplegia, Hereditary",[1515,1533],"Tahor",{"trials":1535,"activeCount":98},[],{"trials":1537,"activeCount":98},[],{"trials":1539,"activeCount":98},[],{"intervention":1533,"totalTrials":94,"cells":1541},{"EARLY_PHASE1":1542,"PHASE1":1544,"PHASE2":1546,"PHASE3":1552,"PHASE4":1554,"NA":1556},{"trials":1543,"activeCount":98},[],{"trials":1545,"activeCount":98},[],{"trials":1547,"activeCount":98},[1548],{"nctId":1524,"briefTitle":1525,"status":246,"phases":1549,"primaryCompletion":1527,"completion":1528,"start":1529,"enrollment":1286,"conditions":1550,"interventions":1551},[88],[1531],[1515,1533],{"trials":1553,"activeCount":98},[],{"trials":1555,"activeCount":98},[],{"trials":1557,"activeCount":98},[],{"intervention":1559,"totalTrials":94,"cells":1560},"6-DIG",{"EARLY_PHASE1":1561,"PHASE1":1563,"PHASE2":1565,"PHASE3":1581,"PHASE4":1583,"NA":1585},{"trials":1562,"activeCount":98},[],{"trials":1564,"activeCount":98},[],{"trials":1566,"activeCount":98},[1567],{"nctId":1568,"briefTitle":1569,"status":246,"phases":1570,"primaryCompletion":1571,"completion":1571,"start":1572,"enrollment":1573,"conditions":1574,"interventions":1580},"NCT02102737","Comparison of A New Technique of Measure of the Insulin Resistance By Scintigraphy With the Reference Technique",[88],"2018-03","2014-05-13",40,[1575,1576,1577,1578,1579],"Diabetes Mellitus","Insulin Resistance","Glucose Metabolism Disorders","Metabolic Diseases","Endocrine System Diseases",[1559],{"trials":1582,"activeCount":98},[],{"trials":1584,"activeCount":98},[],{"trials":1586,"activeCount":98},[],{"intervention":1588,"totalTrials":94,"cells":1589},"Triheptanoin 1g\u002Fkg\u002Fday",{"EARLY_PHASE1":1590,"PHASE1":1592,"PHASE2":1594,"PHASE3":1604,"PHASE4":1606,"NA":1608},{"trials":1591,"activeCount":98},[],{"trials":1593,"activeCount":98},[],{"trials":1595,"activeCount":98},[1596],{"nctId":1597,"briefTitle":1598,"status":246,"phases":1599,"primaryCompletion":1600,"completion":1600,"start":1601,"enrollment":1276,"conditions":1602,"interventions":1603},"NCT01882062","Proof of Concept of an Anaplerotic Study Using Brain Phosphorus Magnetic Resonance Spectroscopy in Huntington Disease",[88],"2013-07","2013-05",[25],[1588],{"trials":1605,"activeCount":98},[],{"trials":1607,"activeCount":98},[],{"trials":1609,"activeCount":98},[],{"intervention":1611,"totalTrials":94,"cells":1612},"Galantamine",{"EARLY_PHASE1":1613,"PHASE1":1615,"PHASE2":1617,"PHASE3":1629,"PHASE4":1631,"NA":1633},{"trials":1614,"activeCount":98},[],{"trials":1616,"activeCount":98},[],{"trials":1618,"activeCount":98},[1619],{"nctId":1620,"briefTitle":1621,"status":246,"phases":1622,"primaryCompletion":1333,"completion":1623,"start":1624,"enrollment":1625,"conditions":1626,"interventions":1628},"NCT01508494","Cognitive Rehabilitation and Galantamine for Post Stroke Cognitive Impairment",[88],"2016-06-22","2011-06-29",47,[20,1627],"Cognitive Impairment",[1611],{"trials":1630,"activeCount":98},[],{"trials":1632,"activeCount":98},[],{"trials":1634,"activeCount":98},[],{"intervention":1636,"totalTrials":94,"cells":1637},"Spironolactone",{"EARLY_PHASE1":1638,"PHASE1":1640,"PHASE2":1642,"PHASE3":1653,"PHASE4":1655,"NA":1657},{"trials":1639,"activeCount":98},[],{"trials":1641,"activeCount":98},[],{"trials":1643,"activeCount":98},[1644],{"nctId":1645,"briefTitle":1646,"status":246,"phases":1647,"primaryCompletion":1648,"completion":1649,"start":1408,"enrollment":1384,"conditions":1650,"interventions":1652},"NCT01552044","Effect of Spironolactone in Treating Chronic Non-resolutive Central Serous Chorioretinitis",[87,88],"2013-01","2013-02",[1651],"Central Serous Chorioretinitis",[1636],{"trials":1654,"activeCount":98},[],{"trials":1656,"activeCount":98},[],{"trials":1658,"activeCount":98},[],{"intervention":1660,"totalTrials":94,"cells":1661},"injection of 6-DIG",{"EARLY_PHASE1":1662,"PHASE1":1664,"PHASE2":1666,"PHASE3":1677,"PHASE4":1679,"NA":1681},{"trials":1663,"activeCount":98},[],{"trials":1665,"activeCount":98},[],{"trials":1667,"activeCount":98},[1668],{"nctId":1669,"briefTitle":1670,"status":246,"phases":1671,"primaryCompletion":1672,"completion":1672,"start":1673,"enrollment":1286,"conditions":1674,"interventions":1676},"NCT01493934","Development of a Fast Measurement Technique of Insulin Resistance in Human",[87,88],"2013-03","2010-04",[1675],"Type 2 Diabetes Mellitus",[1660],{"trials":1678,"activeCount":98},[],{"trials":1680,"activeCount":98},[],{"trials":1682,"activeCount":98},[],{"intervention":1684,"totalTrials":94,"cells":1685},"injection of bone marrow mononucleated cells",{"EARLY_PHASE1":1686,"PHASE1":1688,"PHASE2":1690,"PHASE3":1703,"PHASE4":1705,"NA":1707},{"trials":1687,"activeCount":98},[],{"trials":1689,"activeCount":98},[],{"trials":1691,"activeCount":98},[1692],{"nctId":1693,"briefTitle":1694,"status":246,"phases":1695,"primaryCompletion":1696,"completion":1697,"start":598,"enrollment":1698,"conditions":1699,"interventions":1702},"NCT01089387","Intracavernous Bone Marrow Stem-cell Injection for Post Prostatectomy Erectile Dysfunction",[87,88],"2012-05","2015-03",18,[1700,1701],"Prostate Cancer","Erectile Dysfunction",[1684],{"trials":1704,"activeCount":98},[],{"trials":1706,"activeCount":98},[],{"trials":1708,"activeCount":98},[],{"intervention":1710,"totalTrials":94,"cells":1711},"everolimus",{"EARLY_PHASE1":1712,"PHASE1":1714,"PHASE2":1716,"PHASE3":1727,"PHASE4":1729,"NA":1731},{"trials":1713,"activeCount":98},[],{"trials":1715,"activeCount":98},[],{"trials":1717,"activeCount":98},[1718],{"nctId":1719,"briefTitle":1720,"status":258,"phases":1721,"primaryCompletion":1722,"completion":1722,"start":1723,"enrollment":16,"conditions":1724,"interventions":1726},"NCT01412515","A Phase II Study With Tumor Molecular Pharmacodynamic (MPD) Evaluation of Oral mTOR-inhibitor Everolimus (RAD001) 10 mg Daily in Patients Suffering From Classic or Endemic Kaposi's Sarcoma",[88],"2011-05","2008-06",[1725],"Kaposi Sarcoma",[1710],{"trials":1728,"activeCount":98},[],{"trials":1730,"activeCount":98},[],{"trials":1732,"activeCount":98},[],{"intervention":1734,"totalTrials":94,"cells":1735},"PPS",{"EARLY_PHASE1":1736,"PHASE1":1738,"PHASE2":1740,"PHASE3":1751,"PHASE4":1753,"NA":1755},{"trials":1737,"activeCount":98},[],{"trials":1739,"activeCount":98},[],{"trials":1741,"activeCount":98},[1742],{"nctId":1743,"briefTitle":1744,"status":258,"phases":1745,"primaryCompletion":1672,"completion":1672,"start":985,"enrollment":1746,"conditions":1747,"interventions":1749},"NCT01489618","\"Prime Boost\" Vaccination Strategy Combining Conjugated Anti- Pneumococcal Vaccine (s0) and Polysaccharide Anti- Pneumococcal Vaccine (s4) Compared to Polysaccharide Anti- Pneumococcal Vaccine Alone (s4) In Patients With Common Variable Immunodeficiency",[88],45,[1748],"Common Variable Immunodeficiency",[1734,1750],"PnCJ PPS",{"trials":1752,"activeCount":98},[],{"trials":1754,"activeCount":98},[],{"trials":1756,"activeCount":98},[],{"intervention":1750,"totalTrials":94,"cells":1758},{"EARLY_PHASE1":1759,"PHASE1":1761,"PHASE2":1763,"PHASE3":1769,"PHASE4":1771,"NA":1773},{"trials":1760,"activeCount":98},[],{"trials":1762,"activeCount":98},[],{"trials":1764,"activeCount":98},[1765],{"nctId":1743,"briefTitle":1744,"status":258,"phases":1766,"primaryCompletion":1672,"completion":1672,"start":985,"enrollment":1746,"conditions":1767,"interventions":1768},[88],[1748],[1734,1750],{"trials":1770,"activeCount":98},[],{"trials":1772,"activeCount":98},[],{"trials":1774,"activeCount":98},[],{"intervention":1776,"totalTrials":94,"cells":1777},"50 mL of sodium chloride",{"EARLY_PHASE1":1778,"PHASE1":1780,"PHASE2":1782,"PHASE3":1795,"PHASE4":1797,"NA":1799},{"trials":1779,"activeCount":98},[],{"trials":1781,"activeCount":98},[],{"trials":1783,"activeCount":98},[1784],{"nctId":1785,"briefTitle":1786,"status":246,"phases":1787,"primaryCompletion":260,"completion":1788,"start":1789,"enrollment":1790,"conditions":1791,"interventions":1792},"NCT02267304","Double Blind Randomized, Monocentric, Cross-over, Placebo-controlled Study to Evaluate the Effect of Morphine and Naloxone on Motivation (MBBAnalgesic)",[88],"2016-08-30","2013-10-30",37,[15],[1776,1793,1794],"Morphine 0,05mg\u002Fkg","Naloxone 10mg",{"trials":1796,"activeCount":98},[],{"trials":1798,"activeCount":98},[],{"trials":1800,"activeCount":98},[],{"intervention":1793,"totalTrials":94,"cells":1802},{"EARLY_PHASE1":1803,"PHASE1":1805,"PHASE2":1807,"PHASE3":1813,"PHASE4":1815,"NA":1817},{"trials":1804,"activeCount":98},[],{"trials":1806,"activeCount":98},[],{"trials":1808,"activeCount":98},[1809],{"nctId":1785,"briefTitle":1786,"status":246,"phases":1810,"primaryCompletion":260,"completion":1788,"start":1789,"enrollment":1790,"conditions":1811,"interventions":1812},[88],[15],[1776,1793,1794],{"trials":1814,"activeCount":98},[],{"trials":1816,"activeCount":98},[],{"trials":1818,"activeCount":98},[],{"intervention":1794,"totalTrials":94,"cells":1820},{"EARLY_PHASE1":1821,"PHASE1":1823,"PHASE2":1825,"PHASE3":1831,"PHASE4":1833,"NA":1835},{"trials":1822,"activeCount":98},[],{"trials":1824,"activeCount":98},[],{"trials":1826,"activeCount":98},[1827],{"nctId":1785,"briefTitle":1786,"status":246,"phases":1828,"primaryCompletion":260,"completion":1788,"start":1789,"enrollment":1790,"conditions":1829,"interventions":1830},[88],[15],[1776,1793,1794],{"trials":1832,"activeCount":98},[],{"trials":1834,"activeCount":98},[],{"trials":1836,"activeCount":98},[],{"intervention":1838,"totalTrials":94,"cells":1839},"curcuma longa",{"EARLY_PHASE1":1840,"PHASE1":1842,"PHASE2":1844,"PHASE3":1855,"PHASE4":1857,"NA":1859},{"trials":1841,"activeCount":98},[],{"trials":1843,"activeCount":98},[],{"trials":1845,"activeCount":98},[1846],{"nctId":1847,"briefTitle":1848,"status":246,"phases":1849,"primaryCompletion":1850,"completion":1851,"start":1850,"enrollment":1698,"conditions":1852,"interventions":1854},"NCT01489592","Effect of Curcumin on Iron Metabolism in Healthy Volunteer",[88],"2011-10","2012-03",[1853],"Healthy Volunteers",[1838],{"trials":1856,"activeCount":98},[],{"trials":1858,"activeCount":98},[],{"trials":1860,"activeCount":98},[],{"intervention":1862,"totalTrials":94,"cells":1863},"inactivated non adjuvanted pandemic H1N1 vaccine",{"EARLY_PHASE1":1864,"PHASE1":1866,"PHASE2":1868,"PHASE3":1879,"PHASE4":1881,"NA":1883},{"trials":1865,"activeCount":98},[],{"trials":1867,"activeCount":98},[],{"trials":1869,"activeCount":98},[1870],{"nctId":1871,"briefTitle":1872,"status":246,"phases":1873,"primaryCompletion":1407,"completion":598,"start":1383,"enrollment":1874,"conditions":1875,"interventions":1878},"NCT01086904","Safety and Efficacy of an Inactivated and Non Adjuvanted Vaccine Against Influenza A in Renal Transplant Recipients",[88],122,[1876,1877],"Renal Transplant Recipients","Immunosuppression",[1862],{"trials":1880,"activeCount":98},[],{"trials":1882,"activeCount":98},[],{"trials":1884,"activeCount":98},[],{"intervention":1886,"totalTrials":262,"cells":1887},"Sitagliptin",{"EARLY_PHASE1":1888,"PHASE1":1890,"PHASE2":1909,"PHASE3":1911,"PHASE4":1913,"NA":1915},{"trials":1889,"activeCount":98},[],{"trials":1891,"activeCount":98},[1892,1899],{"nctId":1893,"briefTitle":1894,"status":258,"phases":1895,"primaryCompletion":305,"completion":305,"start":1672,"enrollment":189,"conditions":1896,"interventions":1898},"NCT01567540","A Pilot Study Evaluating Safety of Sitagliptin Combined With Peg-IFN Alfa-2a + Ribavirin in Chronic Hepatitis C Patients",[87],[1897],"Hepatitis C",[1886],{"nctId":1900,"briefTitle":1901,"status":246,"phases":1902,"primaryCompletion":1903,"completion":1903,"start":1904,"enrollment":1905,"conditions":1906,"interventions":1908},"NCT02650427","A Pilot Study to Evaluate the Safety of a 3 Weeks Sitagliptin Treatment in HCC Patients Undergoing Liver Resection",[87],"2018-09","2016-02",14,[1907],"Hepato Carcinoma",[1886],{"trials":1910,"activeCount":98},[],{"trials":1912,"activeCount":98},[],{"trials":1914,"activeCount":98},[],{"trials":1916,"activeCount":98},[],{"intervention":1918,"totalTrials":262,"cells":1919},"BPZE1",{"EARLY_PHASE1":1920,"PHASE1":1922,"PHASE2":1942,"PHASE3":1944,"PHASE4":1946,"NA":1948},{"trials":1921,"activeCount":98},[],{"trials":1923,"activeCount":98},[1924,1934],{"nctId":1925,"briefTitle":1926,"status":246,"phases":1927,"primaryCompletion":1928,"completion":959,"start":249,"enrollment":1929,"conditions":1930,"interventions":1933},"NCT02453048","Study of BPZE1 (High Dose) Nasal Live Attenuated B. Pertussis Vaccine",[87],"2017-03",54,[1931,1932],"Pertussis","Whooping Cough",[1918],{"nctId":1935,"briefTitle":1936,"status":246,"phases":1937,"primaryCompletion":1938,"completion":1408,"start":1939,"enrollment":987,"conditions":1940,"interventions":1941},"NCT01188512","First Adult Safety Trial on Nasal Live Attenuated B. Pertussis Vaccine",[87],"2011-06","2010-08",[1931],[1918],{"trials":1943,"activeCount":98},[],{"trials":1945,"activeCount":98},[],{"trials":1947,"activeCount":98},[],{"trials":1949,"activeCount":98},[],{"intervention":1951,"totalTrials":94,"cells":1952},"DNA vaccine",{"EARLY_PHASE1":1953,"PHASE1":1955,"PHASE2":1966,"PHASE3":1968,"PHASE4":1970,"NA":1972},{"trials":1954,"activeCount":98},[],{"trials":1956,"activeCount":98},[1957],{"nctId":1958,"briefTitle":1959,"status":246,"phases":1960,"primaryCompletion":1961,"completion":1157,"start":1962,"enrollment":1276,"conditions":1963,"interventions":1965},"NCT00988767","Safety and Immunogenicity of a Naked DNA-based Vaccine Therapy in Patients With Chronic Hepatitis B",[87],"2003-11","2001-02",[1964],"Chronic Hepatitis B",[1951],{"trials":1967,"activeCount":98},[],{"trials":1969,"activeCount":98},[],{"trials":1971,"activeCount":98},[],{"trials":1973,"activeCount":98},[],{"intervention":1975,"totalTrials":94,"cells":1976},"FLAMOD",{"EARLY_PHASE1":1977,"PHASE1":1979,"PHASE2":1991,"PHASE3":1993,"PHASE4":1995,"NA":1997},{"trials":1978,"activeCount":98},[],{"trials":1980,"activeCount":98},[1981],{"nctId":1982,"briefTitle":1983,"status":246,"phases":1984,"primaryCompletion":1985,"completion":1985,"start":1986,"enrollment":1987,"conditions":1988,"interventions":1990},"NCT06681402","Phase I Single-blind Clinical Trial to Evaluate the Safety and Local Immune Activation of a Toll-like Receptor 5 Agonist (FLAMOD) Administered by Aerosol",[87],"2026-04-17","2025-04-14",46,[1989],"Pneumonia",[1975],{"trials":1992,"activeCount":98},[],{"trials":1994,"activeCount":98},[],{"trials":1996,"activeCount":98},[],{"trials":1998,"activeCount":98},[],{"intervention":2000,"totalTrials":94,"cells":2001},"Gepotidacin",{"EARLY_PHASE1":2002,"PHASE1":2004,"PHASE2":2017,"PHASE3":2019,"PHASE4":2021,"NA":2023},{"trials":2003,"activeCount":98},[],{"trials":2005,"activeCount":98},[2006],{"nctId":2007,"briefTitle":2008,"status":246,"phases":2009,"primaryCompletion":2010,"completion":2010,"start":2011,"enrollment":2012,"conditions":2013,"interventions":2016},"NCT04484740","Penetration of the Innovative Antibiotic Gepotidacin Into Prostate and Tonsillar Tissue",[87],"2023-05-27","2021-01-29",53,[2014,2015],"Gonorrhea","Infection, Bacterial",[2000],{"trials":2018,"activeCount":98},[],{"trials":2020,"activeCount":98},[],{"trials":2022,"activeCount":98},[],{"trials":2024,"activeCount":98},[],{"intervention":2026,"totalTrials":94,"cells":2027},"PRIMVAC",{"EARLY_PHASE1":2028,"PHASE1":2030,"PHASE2":2045,"PHASE3":2047,"PHASE4":2049,"NA":2051},{"trials":2029,"activeCount":98},[],{"trials":2031,"activeCount":98},[2032],{"nctId":2033,"briefTitle":2034,"status":246,"phases":2035,"primaryCompletion":2036,"completion":2037,"start":2038,"enrollment":2039,"conditions":2040,"interventions":2042},"NCT02658253","Trial to Evaluate the Safety and Immunogenicity of a Placental Malaria Vaccine Candidate (PRIMVAC ) in Healthy Adults",[87],"2018-09-19","2019-02-21","2016-01",68,[2041],"Malaria",[2026,2043,2044],"GLA-SE","Alhydrogel",{"trials":2046,"activeCount":98},[],{"trials":2048,"activeCount":98},[],{"trials":2050,"activeCount":98},[],{"trials":2052,"activeCount":98},[],{"intervention":2043,"totalTrials":94,"cells":2054},{"EARLY_PHASE1":2055,"PHASE1":2057,"PHASE2":2063,"PHASE3":2065,"PHASE4":2067,"NA":2069},{"trials":2056,"activeCount":98},[],{"trials":2058,"activeCount":98},[2059],{"nctId":2033,"briefTitle":2034,"status":246,"phases":2060,"primaryCompletion":2036,"completion":2037,"start":2038,"enrollment":2039,"conditions":2061,"interventions":2062},[87],[2041],[2026,2043,2044],{"trials":2064,"activeCount":98},[],{"trials":2066,"activeCount":98},[],{"trials":2068,"activeCount":98},[],{"trials":2070,"activeCount":98},[],{"intervention":2044,"totalTrials":94,"cells":2072},{"EARLY_PHASE1":2073,"PHASE1":2075,"PHASE2":2081,"PHASE3":2083,"PHASE4":2085,"NA":2087},{"trials":2074,"activeCount":98},[],{"trials":2076,"activeCount":98},[2077],{"nctId":2033,"briefTitle":2034,"status":246,"phases":2078,"primaryCompletion":2036,"completion":2037,"start":2038,"enrollment":2039,"conditions":2079,"interventions":2080},[87],[2041],[2026,2043,2044],{"trials":2082,"activeCount":98},[],{"trials":2084,"activeCount":98},[],{"trials":2086,"activeCount":98},[],{"trials":2088,"activeCount":98},[],{"intervention":2090,"totalTrials":94,"cells":2091},"10 parents drugs adminstration",{"EARLY_PHASE1":2092,"PHASE1":2094,"PHASE2":2103,"PHASE3":2105,"PHASE4":2107,"NA":2109},{"trials":2093,"activeCount":98},[],{"trials":2095,"activeCount":98},[2096],{"nctId":2097,"briefTitle":2098,"status":246,"phases":2099,"primaryCompletion":2100,"completion":2100,"start":1939,"enrollment":1276,"conditions":2101,"interventions":2102},"NCT01188525","Pharmacokinetic Study to Characterize Individual Metabolic Profile",[87],"2011-07",[1853],[2090],{"trials":2104,"activeCount":98},[],{"trials":2106,"activeCount":98},[],{"trials":2108,"activeCount":98},[],{"trials":2110,"activeCount":98},[],{"intervention":2112,"totalTrials":94,"cells":2113},"Group A1 : 50µg AMA1-DiCo + Alhydrogel",{"EARLY_PHASE1":2114,"PHASE1":2116,"PHASE2":2128,"PHASE3":2130,"PHASE4":2132,"NA":2134},{"trials":2115,"activeCount":98},[],{"trials":2117,"activeCount":98},[2118],{"nctId":2119,"briefTitle":2120,"status":246,"phases":2121,"primaryCompletion":1697,"completion":2122,"start":305,"enrollment":167,"conditions":2123,"interventions":2125},"NCT02014727","Safety and Immunogenicity of Recombinant Pichia Pastoris AMA1-DiCo Candidate Malaria Vaccine With GLA-SE and Alhydrogel ® as Adjuvant in Healthy Malaria Non-Exposed European and Malaria Exposed African Adults",[87],"2015-07",[2124],"Malaria, Falciparum",[2112,2126,2127],"Group A2 : 50 µg AMA1-DiCo+ GLA-SE","Group B2 : Placebo",{"trials":2129,"activeCount":98},[],{"trials":2131,"activeCount":98},[],{"trials":2133,"activeCount":98},[],{"trials":2135,"activeCount":98},[],{"intervention":2126,"totalTrials":94,"cells":2137},{"EARLY_PHASE1":2138,"PHASE1":2140,"PHASE2":2146,"PHASE3":2148,"PHASE4":2150,"NA":2152},{"trials":2139,"activeCount":98},[],{"trials":2141,"activeCount":98},[2142],{"nctId":2119,"briefTitle":2120,"status":246,"phases":2143,"primaryCompletion":1697,"completion":2122,"start":305,"enrollment":167,"conditions":2144,"interventions":2145},[87],[2124],[2112,2126,2127],{"trials":2147,"activeCount":98},[],{"trials":2149,"activeCount":98},[],{"trials":2151,"activeCount":98},[],{"trials":2153,"activeCount":98},[],{"intervention":2127,"totalTrials":94,"cells":2155},{"EARLY_PHASE1":2156,"PHASE1":2158,"PHASE2":2164,"PHASE3":2166,"PHASE4":2168,"NA":2170},{"trials":2157,"activeCount":98},[],{"trials":2159,"activeCount":98},[2160],{"nctId":2119,"briefTitle":2120,"status":246,"phases":2161,"primaryCompletion":1697,"completion":2122,"start":305,"enrollment":167,"conditions":2162,"interventions":2163},[87],[2124],[2112,2126,2127],{"trials":2165,"activeCount":98},[],{"trials":2167,"activeCount":98},[],{"trials":2169,"activeCount":98},[],{"trials":2171,"activeCount":98},[],{"intervention":2173,"totalTrials":94,"cells":2174},"Ritalin (methylphenidate)10Mg",{"EARLY_PHASE1":2175,"PHASE1":2189,"PHASE2":2191,"PHASE3":2193,"PHASE4":2195,"NA":2197},{"trials":2176,"activeCount":98},[2177],{"nctId":2178,"briefTitle":2179,"status":246,"phases":2180,"primaryCompletion":2181,"completion":2181,"start":2182,"enrollment":2183,"conditions":2184,"interventions":2188},"NCT03190681","Motivation and Methylphenidate",[86],"2017-11-15","2017-07-11",35,[2185,2186,2187],"Motivation","Apathy","Impulsive Behavior",[2173],{"trials":2190,"activeCount":98},[],{"trials":2192,"activeCount":98},[],{"trials":2194,"activeCount":98},[],{"trials":2196,"activeCount":98},[],{"trials":2198,"activeCount":98},[],{"intervention":2200,"totalTrials":94,"cells":2201},"Sequencing",{"EARLY_PHASE1":2202,"PHASE1":2204,"PHASE2":2206,"PHASE3":2208,"PHASE4":2210,"NA":2212},{"trials":2203,"activeCount":98},[],{"trials":2205,"activeCount":98},[],{"trials":2207,"activeCount":98},[],{"trials":2209,"activeCount":98},[],{"trials":2211,"activeCount":98},[],{"trials":2213,"activeCount":98},[2214],{"nctId":2215,"briefTitle":2216,"status":258,"phases":2217,"primaryCompletion":2218,"completion":2219,"start":2220,"enrollment":2221,"conditions":2222,"interventions":2224},"NCT04322279","Factors Associated With a Positive SARS-CoV-2 Serology in Contact Subjects at High\u002FModerate Risk of Coronavirus SARS-CoV-2 Infection. COVID-19.",[],"2021-12-31","2022-12-31","2020-03-09",81,[2223],"Coronavirus",[2200],{"intervention":2226,"totalTrials":94,"cells":2227},"ROUVAX",{"EARLY_PHASE1":2228,"PHASE1":2230,"PHASE2":2232,"PHASE3":2234,"PHASE4":2236,"NA":2238},{"trials":2229,"activeCount":98},[],{"trials":2231,"activeCount":98},[],{"trials":2233,"activeCount":98},[],{"trials":2235,"activeCount":98},[],{"trials":2237,"activeCount":98},[],{"trials":2239,"activeCount":98},[2240],{"nctId":2241,"briefTitle":2242,"status":246,"phases":2243,"primaryCompletion":2244,"completion":2244,"start":2245,"enrollment":306,"conditions":2246,"interventions":2248},"NCT00820820","IDA (Immunothérapie de la Dermatite Atopique) Adult - Immunotherapy in Atopic Dermatitis",[91],"2012-03-26","2009-01-09",[2247],"Atopic Dermatitis",[2226],{"intervention":2250,"totalTrials":94,"cells":2251},"Case-control transcriptomic study",{"EARLY_PHASE1":2252,"PHASE1":2254,"PHASE2":2256,"PHASE3":2258,"PHASE4":2260,"NA":2262},{"trials":2253,"activeCount":98},[],{"trials":2255,"activeCount":98},[],{"trials":2257,"activeCount":98},[],{"trials":2259,"activeCount":98},[],{"trials":2261,"activeCount":98},[],{"trials":2263,"activeCount":98},[2264],{"nctId":2265,"briefTitle":2266,"status":246,"phases":2267,"primaryCompletion":2268,"completion":2268,"start":2269,"enrollment":2270,"conditions":2271,"interventions":2274},"NCT01779713","Transcriptomic Signature of Vasospasm Consecutive to Sub-arachnoid Aneurismal Hemorrhage",[],"2016-08-15","2013-02-04",89,[2272,2273],"Aneurysmal Subarachnoid Hemorrhage","Vasospasm",[2250],{"intervention":2276,"totalTrials":94,"cells":2277},"Trio Whole Genome Sequencing",{"EARLY_PHASE1":2278,"PHASE1":2280,"PHASE2":2282,"PHASE3":2284,"PHASE4":2286,"NA":2288},{"trials":2279,"activeCount":98},[],{"trials":2281,"activeCount":98},[],{"trials":2283,"activeCount":98},[],{"trials":2285,"activeCount":98},[],{"trials":2287,"activeCount":98},[],{"trials":2289,"activeCount":98},[2290],{"nctId":2291,"briefTitle":2292,"status":246,"phases":2293,"primaryCompletion":2294,"completion":2295,"start":2296,"enrollment":2297,"conditions":2298,"interventions":2299},"NCT04154891","Genome Sequencing Strategies for Genetics Diagnosis of Patients With Intellectual Disability",[91],"2023-12-31","2025-06-16","2020-03-13",3825,[431],[2276,2300,2301],"Simplex Whole Genome Sequencing","Current French Reference strategy",{"intervention":2300,"totalTrials":94,"cells":2303},{"EARLY_PHASE1":2304,"PHASE1":2306,"PHASE2":2308,"PHASE3":2310,"PHASE4":2312,"NA":2314},{"trials":2305,"activeCount":98},[],{"trials":2307,"activeCount":98},[],{"trials":2309,"activeCount":98},[],{"trials":2311,"activeCount":98},[],{"trials":2313,"activeCount":98},[],{"trials":2315,"activeCount":98},[2316],{"nctId":2291,"briefTitle":2292,"status":246,"phases":2317,"primaryCompletion":2294,"completion":2295,"start":2296,"enrollment":2297,"conditions":2318,"interventions":2319},[91],[431],[2276,2300,2301],{"intervention":2301,"totalTrials":94,"cells":2321},{"EARLY_PHASE1":2322,"PHASE1":2324,"PHASE2":2326,"PHASE3":2328,"PHASE4":2330,"NA":2332},{"trials":2323,"activeCount":98},[],{"trials":2325,"activeCount":98},[],{"trials":2327,"activeCount":98},[],{"trials":2329,"activeCount":98},[],{"trials":2331,"activeCount":98},[],{"trials":2333,"activeCount":98},[2334],{"nctId":2291,"briefTitle":2292,"status":246,"phases":2335,"primaryCompletion":2294,"completion":2295,"start":2296,"enrollment":2297,"conditions":2336,"interventions":2337},[91],[431],[2276,2300,2301],{"intervention":2339,"totalTrials":94,"cells":2340},"Sampling",{"EARLY_PHASE1":2341,"PHASE1":2343,"PHASE2":2345,"PHASE3":2347,"PHASE4":2349,"NA":2351},{"trials":2342,"activeCount":98},[],{"trials":2344,"activeCount":98},[],{"trials":2346,"activeCount":98},[],{"trials":2348,"activeCount":98},[],{"trials":2350,"activeCount":98},[],{"trials":2352,"activeCount":98},[2353],{"nctId":2354,"briefTitle":2355,"status":246,"phases":2356,"primaryCompletion":2357,"completion":2357,"start":2358,"enrollment":2359,"conditions":2360,"interventions":2362},"NCT01258036","Mother Daughter Bone Microarchitecture",[],"2012-02-29","2010-05-04",1040,[2361],"Bone Fragility",[2339],{"intervention":2364,"totalTrials":94,"cells":2365},"gene analysis",{"EARLY_PHASE1":2366,"PHASE1":2368,"PHASE2":2370,"PHASE3":2372,"PHASE4":2374,"NA":2376},{"trials":2367,"activeCount":98},[],{"trials":2369,"activeCount":98},[],{"trials":2371,"activeCount":98},[],{"trials":2373,"activeCount":98},[],{"trials":2375,"activeCount":98},[],{"trials":2377,"activeCount":98},[2378],{"nctId":2379,"briefTitle":2380,"status":246,"phases":2381,"primaryCompletion":2219,"completion":2219,"start":2382,"enrollment":2383,"conditions":2384,"interventions":2385},"NCT01867554","Research and Characterization of New Genes Involved in Intellectual Disability",[],"2012-12-31",8500,[431],[2364],{"intervention":2387,"totalTrials":94,"cells":2388},"Non applicable",{"EARLY_PHASE1":2389,"PHASE1":2391,"PHASE2":2393,"PHASE3":2395,"PHASE4":2397,"NA":2399},{"trials":2390,"activeCount":98},[],{"trials":2392,"activeCount":98},[],{"trials":2394,"activeCount":98},[],{"trials":2396,"activeCount":98},[],{"trials":2398,"activeCount":98},[],{"trials":2400,"activeCount":98},[2401],{"nctId":2402,"briefTitle":2403,"status":246,"phases":2404,"primaryCompletion":2219,"completion":2405,"start":2406,"enrollment":2407,"conditions":2408,"interventions":2410},"NCT04392388","Health, Perception, Practices, Relations and Social Inequalities in the General Population During the Covid-19 Crisis",[],"2023-04-11","2020-05-01",96883,[2409],"SARS-CoV 2",[2387],{"intervention":2412,"totalTrials":94,"cells":2413},"Next Generation Sequencing (NGS): exome, RNA seq",{"EARLY_PHASE1":2414,"PHASE1":2416,"PHASE2":2418,"PHASE3":2420,"PHASE4":2422,"NA":2424},{"trials":2415,"activeCount":98},[],{"trials":2417,"activeCount":98},[],{"trials":2419,"activeCount":98},[],{"trials":2421,"activeCount":98},[],{"trials":2423,"activeCount":98},[],{"trials":2425,"activeCount":98},[2426],{"nctId":2427,"briefTitle":2428,"status":246,"phases":2429,"primaryCompletion":2430,"completion":2430,"start":2431,"enrollment":873,"conditions":2432,"interventions":2434},"NCT03546127","Molecular Profiling to Improve Outcome of Patients in Cancer. A Pilot Study",[],"2017-09-21","2017-05-23",[2433,652],"Colorectal Carcinoma",[2412],{"intervention":2436,"totalTrials":94,"cells":2437},"Whole genome sequencing and Genome-Epigenome-Phenome Associations",{"EARLY_PHASE1":2438,"PHASE1":2440,"PHASE2":2442,"PHASE3":2444,"PHASE4":2446,"NA":2448},{"trials":2439,"activeCount":98},[],{"trials":2441,"activeCount":98},[],{"trials":2443,"activeCount":98},[],{"trials":2445,"activeCount":98},[],{"trials":2447,"activeCount":98},[],{"trials":2449,"activeCount":98},[2450],{"nctId":2451,"briefTitle":2452,"status":246,"phases":2453,"primaryCompletion":2454,"completion":2454,"start":2455,"enrollment":2456,"conditions":2457,"interventions":2459},"NCT06260319","Decoding Developmental Disorders in Humams",[],"2024-01-01","2019-01-01",720,[2458],"Genetic Diseases",[2436],{"intervention":2461,"totalTrials":94,"cells":2462},"2019-nCoV PCR",{"EARLY_PHASE1":2463,"PHASE1":2465,"PHASE2":2467,"PHASE3":2469,"PHASE4":2471,"NA":2473},{"trials":2464,"activeCount":98},[],{"trials":2466,"activeCount":98},[],{"trials":2468,"activeCount":98},[],{"trials":2470,"activeCount":98},[],{"trials":2472,"activeCount":98},[],{"trials":2474,"activeCount":98},[2475],{"nctId":2476,"briefTitle":2477,"status":246,"phases":2478,"primaryCompletion":2479,"completion":2479,"start":2480,"enrollment":2481,"conditions":2482,"interventions":2483},"NCT04259892","Viral Excretion in Contact Subjects at High\u002FModerate Risk of Coronavirus 2019-nCoV Infection. COVID-19.",[],"2021-08-02","2020-02-04",324,[2223],[2461],{"intervention":2485,"totalTrials":94,"cells":2486},"pneumovax vaccination",{"EARLY_PHASE1":2487,"PHASE1":2489,"PHASE2":2491,"PHASE3":2493,"PHASE4":2495,"NA":2497},{"trials":2488,"activeCount":98},[],{"trials":2490,"activeCount":98},[],{"trials":2492,"activeCount":98},[],{"trials":2494,"activeCount":98},[],{"trials":2496,"activeCount":98},[],{"trials":2498,"activeCount":98},[2499],{"nctId":2500,"briefTitle":2501,"status":246,"phases":2502,"primaryCompletion":261,"completion":2503,"start":2504,"enrollment":21,"conditions":2505,"interventions":2507},"NCT02126384","Identifocation the B Cell Subsets Responsible for Anti-pneumococcal Response",[91],"2016-04-05","2014-11-18",[2506],"Pneumococcal Diseases",[2485],{"intervention":2509,"totalTrials":94,"cells":2510},"Neurohormonal mechanisms",{"EARLY_PHASE1":2511,"PHASE1":2513,"PHASE2":2515,"PHASE3":2517,"PHASE4":2519,"NA":2521},{"trials":2512,"activeCount":98},[],{"trials":2514,"activeCount":98},[],{"trials":2516,"activeCount":98},[],{"trials":2518,"activeCount":98},[],{"trials":2520,"activeCount":98},[],{"trials":2522,"activeCount":98},[2523],{"nctId":2524,"briefTitle":2525,"status":246,"phases":2526,"primaryCompletion":2527,"completion":2528,"start":2529,"enrollment":167,"conditions":2530,"interventions":2534},"NCT03272230","Assessment of Apathy in a Real-life Situation, With a Video and Sensors-based System",[91],"2023-12-08","2024-05-08","2017-09-06",[2186,2531,2532,2533],"Behavioral Variant Frontotemporal Dementia (bvFTD)","Disinhibition","Depression - Major Depressive Disorder",[2509]]